Argent Biopharma logo
RGT
Pharmaceuticals, Biotechnology & Life Sciences

Argent Biopharma

Short interest
0.00%
0.00 pp 30d
as of 19 Aug 2024
Reported shorts
1
Shares on issue
48.406M

Argent Biopharma (RGT) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Neutral
3 Aug

Argent Biopharma Limited Announces Expiry and Cessation of 181,422 Options on 31 July 2026

Argent Biopharma Limited (ASX:RGT) has informed the ASX about the expiry and subsequent cessation of 181,422 unquoted options that lapsed on 31 July 2026 without being exercised or converted, as detailed in an Appendix 3H filing submitted on 3 August 2026. Key Highlights A total of 181,422 options under security code RGTAAI, each with an exercise price of $3.00, expired on 31 July 2026 without exercise or conversion. The options ceased solely due to expiry, with no consideration paid by Argen...

Kalkine
Positive
7 July

Argent BioPharma Licensing Deal Strengthens Global Growth Strategy

Highlights Global licensing agreement strengthens strategic direction. Debt restructuring supports a cleaner financial position. CannEpil remains central to future commercial plans. Argent BioPharma has entered a global licensing agreement for its neurological therapy while retaining ownership of its intellectual property. The transaction simplifies the company’s financial structure, supports future manufacturing opportunities, and aligns with its broade...